FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 181 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... July 23, 2020 Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... May 17, 2021 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... February 25, 2021 Load more HOT NEWS E-cigarettes: what we know and what we don’t Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... Turning the Life Sciences Vision into reality
